Anti-Obesity Drugs Market - Pmr Market Insight Report 2016 to 2022
- Submitted by: justinbarnes123
- Views: 88
- Category: Other
- Date Submitted: 02/08/2016 03:03 AM
- Pages: 4
- Report this Essay
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Persistence Market Research
Anti-Obesity Drugs Market - PMR Market
Insight Report 2016 to 2022
Persistence Market Research
1
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Persistence Market Research Released New Market Report on “Anti-Obesity Drugs
Market - PMR Market Insight Report 2016 to 2022”.
According to World Health Organization (WHO), obesity refers a disorder of
accumulation of excessive fat that can impair health. Body Mass Index (BMI) is an
index of weight for height, which is a measure for classifying obesity and
overweight. According to WHO, BMI greater than or equal to 30 is consider as an
Obese. Anti-obesity drugs refers the drugs that reduces or control the body weight
by either reducing the appetite or increasing the absorption of calories. The
fundamental treatment for obesity is to control over unhealthy diet, and regular
exercise, as although anti-obesity drugs are available in the market, their usefulness
is restricted to maintain weight rather than cure. Obesity is a risk factor for
development of several chronic diseases such as coronary heart diseases,
hypertension, metabolic disorders such as diabetes, and others. Hence, need to
control by proper medication, diet, and exercise. Bariatric surgery is an also option
for weight loss for BMI more than 40. However, lifelong changes in eating and
exercise habits are necessary after surgery.
Global anti-obesity drugs market segmented by approved drugs: buproprion and
naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and
topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global anti-obesity
drugs market segmented into North America, Europe, Asia Pacific, Latin America,
and rest of the World. Presently, North America holds largest share of the market
due to increasing obese population. For instance, according to Centers for Disease
Control and Prevention (CDC), more...
Persistence Market Research
Anti-Obesity Drugs Market - PMR Market
Insight Report 2016 to 2022
Persistence Market Research
1
Anti-Obesity Drugs Market - PMR Market Insight Report 2016 to 2022
Persistence Market Research Released New Market Report on “Anti-Obesity Drugs
Market - PMR Market Insight Report 2016 to 2022”.
According to World Health Organization (WHO), obesity refers a disorder of
accumulation of excessive fat that can impair health. Body Mass Index (BMI) is an
index of weight for height, which is a measure for classifying obesity and
overweight. According to WHO, BMI greater than or equal to 30 is consider as an
Obese. Anti-obesity drugs refers the drugs that reduces or control the body weight
by either reducing the appetite or increasing the absorption of calories. The
fundamental treatment for obesity is to control over unhealthy diet, and regular
exercise, as although anti-obesity drugs are available in the market, their usefulness
is restricted to maintain weight rather than cure. Obesity is a risk factor for
development of several chronic diseases such as coronary heart diseases,
hypertension, metabolic disorders such as diabetes, and others. Hence, need to
control by proper medication, diet, and exercise. Bariatric surgery is an also option
for weight loss for BMI more than 40. However, lifelong changes in eating and
exercise habits are necessary after surgery.
Global anti-obesity drugs market segmented by approved drugs: buproprion and
naltrexone (Contrave), orlistat (Xenical), lorcaserin (Belviq), phentermine and
topiramate (Qsymia), and liraglutide (Saxenda). Geographically, global anti-obesity
drugs market segmented into North America, Europe, Asia Pacific, Latin America,
and rest of the World. Presently, North America holds largest share of the market
due to increasing obese population. For instance, according to Centers for Disease
Control and Prevention (CDC), more...